4.1 Review

Allergic rhinitis

Journal

ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
Volume 14, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13223-018-0280-7

Keywords

-

Funding

  1. AstraZeneca
  2. Boehringer Ingelheim
  3. CSL Behring Canada Inc.
  4. MEDA Pharmaceuticals Ltd.
  5. Merck Canada Inc.
  6. Pfizer Canada Inc.
  7. Shire Pharma Canada ULC
  8. Stallergenes Greer Canada
  9. Takeda Canada
  10. Teva Canada Innovation
  11. Aralez Tribute
  12. Pediapharm

Ask authors/readers for more resources

Allergic rhinitis is a common disorder that is strongly linked to asthma and conjunctivitis. It is usually a long-standing condition that often goes undetected in the primary-care setting. The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea and sneezing. A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis. Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment. Allergen immunotherapy is an effective immune-modulating treatment that should be recommended if pharmacologic therapy for allergic rhinitis is not effective or is not tolerated, or if chosen by the patient. This article provides an overview of the pathophysiology, diagnosis, and appropriate management of this disorder.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available